MAP2K7 and central nervous system cancer: Finally, the MEK inhibitor, binimetinib, was investigated in a non-randomized open-label clinical study in 62 patients with encorafenib, a BRAF inhibitor, in patients with recurrent BRAF V600-mutated high-grade glioma (HGG) [64].